(Q28483861)

1

0 references

Surendra Kumar Agarwal

2

0 references

Shantanu Pande

3

0 references

Sushil Kumar Singh

4

0 references

Tulika Mittal

Creative Commons Attribution 4.0 International

5

0 references

language of work or name

English

0 references

publication date

2012

0 references

published in

PLOS One

0 references

volume

7

0 references

issue

5

0 references

page(s)

e37844

0 references

copyright license

start time

22 May 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Estimation of the warfarin dose with clinical and pharmacogenetic data

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

The largest prospective warfarin-treated cohort supports genetic forecasting

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

CYP4F2 genetic variant alters required warfarin dose

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Pharmacogenetics of target genes across the warfarin pharmacological pathway

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Association of warfarin dose with genes involved in its action and metabolism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Pharmacogenetics of warfarin: current status and future challenges

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Pharmacogenetics and anticoagulant therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Genomic medicine--a primer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Managing oral anticoagulant therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Pharmacogenomics: translating functional genomics into rational therapeutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Antithrombotic therapy in deep vein thrombosis and pulmonary embolism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

29 September 2017

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Tailoring warfarin induction doses to reflect individual and disease-specific factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0037844

Optimization of warfarin dose by population-specific pharmacogenomic algorithm.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Frequencies of VKORC1 -1639 G>A, CYP2C9*2 and CYP2C9*3 genetic variants in the Northern Indian population.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358293

A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance

27 November 2018

1 reference

12 December 2020

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

12 December 2020

Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring

1 reference

12 December 2020

Antithrombotic therapy in atrial fibrillation

1 reference

12 December 2020

Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose

1 reference

12 December 2020

Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes

1 reference

12 December 2020

Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts

1 reference

12 December 2020